N/A N=100 Smell Sensitivity in Chronic Migraine: A Case-Control Study
Chronic Migraine · Olfactory Acuity
Primary: Comparison of UPSIT Scores Between Subjects and Controls at Two Time Points — 34.5; 35.9; 34.7; 36.1 UPSIT Score
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor
Precancerous Conditions
Primary: Dose Escalation and Toxicity: Toxicities Including Grades 1 to 4 — 2; 2; 2; 1 participants
Phase 3 N=58 THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
Breast Cancer
Primary: Progression-Free Survival (PFS) - Percentage of Participants With an Event — 58.6; 58.6 percentage of participants
Phase 1 N=5 Positron Emission Tomography (PET) Study of Brain Calcitonin Gene-Related Peptide (CGRP) Receptor Occupancy After Telcagepant Administration (MK-0974-067)
Migraine
Primary: Number of Participants With Adverse Events (AEs) (Part I) — 4 participants
Phase 4 N=798 Zomig - Treatment of Acute Migraine Headache in Adolescents
Migraine Headache
Primary: Pain-free Status at 2 Hours Post-treatment — 42; 20; 20; 68 Participants — p=.312
Phase 2 N=23 Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics
Asthma · Bronchospasm · Wheezing
Primary: Baseline Concentration (C0) of Total Epinephrine — 2.6; 4.3 pg/mL
Phase 2 N=41 Rapid Acclimatization to Hypoxia at Altitude
Physiological Function in Low Oxygen Environment
Primary: Magnitude of Decrement in Exercise Time Trial Performance in Hypoxia (Low Oxygen) Compared With Normoxia (Normal Oxygen). — 22.3; 25.2; 22.2; 24.0 minutes
N/A N=200 An Intervention Study To Improve Human PapillomaVirus ( HPV) Immunization in Haitian and African American Girls
Cervical Cancer
Primary: The Receipt of the First HPV Vaccination — 51; 56 percentage of participants
Phase 3 N=73 Augmenting Atropine Treatment for Amblyopia in Children 3 to < 8 Years Old
Amblyopia
Primary: Distribution of 10-week Amblyopic-Eye Visual Acuity — 0; 1; 2; 0 participants
Phase 2 N=123 Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures
Partial Epilepsy
Primary: Change From Baseline in Power of Attention Score to the End of the Double Blind (DB) Period — 111.085; 59.122 Milli seconds (ms) — p=0.700
Phase 2 N=12 Evaluation of the Attenuation by Aes-103 of Hypoxia Mediated Decrements in Endurance Exercise Performance
Hypoxia
Primary: Primary Objective Endurance Exercise Performance — 22.4; 24.5; 24.0; 24.6 minutes
Phase 2 N=42 Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia
Myelodysplastic Syndrome
Primary: Red Blood Cell Transfusion Independence — 6; 10; 21 participants
N/A N=402 Effectiveness Study of Community-Based, Peer-Led Education on Weight Loss and Diabetes
Pre-diabetes
Primary: Change in Weight From Baseline to 6 Months — -2.85; -1.13 pounds
N/A N=10 Exercise Intervention to Reduce Postural Instability in Osteoarthritis
Osteoarthritis
Primary: Gait and Balance Measures
Phase 2 N=16 D-cycloserine and Treatment of Feeding Disorders
Feeding Disorders · Specific Phobia
Primary: Rapid Swallowing — 18.6; 14.3 percentage of bites